logo

For the Inventor, By the Inventor

Yateley, United Kingdom

Stephen Richard Baker

This inventor holds 26 USPTO granted patents, primarily in Pharmaceutical Compounds. Top assignees: Eli Lilly and Company, Lilly Industries, Inc., University of East Anglia. Active years: 1981-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen Richard Baker. Retrieved from https://idiyas.com/inventor/stephen-richard-baker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 92.3

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 91(Granted Patents)


Location History:

  • Eversley, GB (1981 - 1987)
  • Indianapolis, IN (US) (1990 - 1991)
  • Surrey, GB (1998 - 1999)
  • Camberley, GB (1987 - 2003)
  • Yateley, GB (1990 - 2006)
  • Isle of Man, GB (2013)

Company Filing History:

goldMedal15 out of 4,514 
 
Eli Lilly and Company
 patents
silverMedal10 out of 158 
 
Lilly Industries, Inc.
 patents
bronzeMedal2 out of 14 
 
University of East Anglia
 patents
4. 1 out of 8 
 
Lilly, Sa
 patents
5. 1 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1981-2013

Loading Chart...
Areas of Expertise:
MGlu 2/3 Agonists
Sulphonamide Derivatives
Naphtalene Derivatives
N-benzyl Indoles
Phenylglycine Derivatives
Tetrahydro-Beta-Carbolines
Tetrazole Compounds
Aminoalkyl-Indoles
Oxiranes
Aurone Derivatives
SRS-A Antagonists
Organic Compounds
26 patents (USPTO):Explore Patents
1. 8575214 - MGlu 2/3 agonists (2013-11-05),
2. 7135487 - Sulphonamide derivatives (2006-11-14),
3. 6846830 - Naphtalene derivatives and their pharmaceutical use (2005-01-25),
4. 6509476 - Process for preparing N-benzyl indoles (2003-01-21),
5. 6303816 - Sulphonamide derivatives (2001-10-16),
6. 6160120 - Process for preparing n-benzyl indoles (2000-12-12),
7. 5906985 - Pharmaceutical compounds (1999-05-25),
8. 5869691 - Aminoalkyl-indoles (1999-02-09),
9. 5863947 - Phenylglycine derivatives useful for treating disorders of the central (1999-01-26),
10. 5861410 - Tetrahydro-beta-carbolines (1999-01-19),
11. 5861409 - Tetrahydro-beta-carbolines (1999-01-19),
12. 5861408 - Tetrahydro-Beta-Carbolines (1999-01-19),
13. 5807866 - Process for preparing N-benzyl indoles (1998-09-15),
14. 5663178 - Tetrahydro-beta carbolines (1997-09-02),
15. 5643916 - Tetrahydro-beta-carbolines (1997-07-01),

Title: The Innovative Journey of Inventor Stephen Richard Baker

Introduction

Stephen Richard Baker, a prolific inventor hailing from Yateley, GB, is renowned for his groundbreaking work in the field of pharmaceuticals. With an impressive portfolio of 26 patents to his name, Baker has significantly contributed to the advancements in treating neurological and psychiatric disorders.

Latest Patents

Baker's latest patents showcase his expertise and ingenuity in the pharmaceutical domain. His invention of novel mGlu 2/3 agonists, designed for the treatment of neurological and psychiatric disorders, highlights his commitment to improving healthcare outcomes. Additionally, the development of sulphonamide derivatives underscores Baker's dedication to exploring new avenues for pharmaceutical therapies.

Career Highlights

Throughout his career, Baker has made notable contributions to esteemed companies such as Eli Lilly and Company and Lilly Industries, Inc. His valuable insights and innovative approach have played a pivotal role in advancing pharmaceutical research and development within these organizations.

Collaborations

Collaborating with esteemed colleagues such as Concepcion Pedregal Tercero and James E Audia, Baker has fostered a culture of innovation and excellence. Together, they have worked tirelessly to push the boundaries of pharmaceutical science and bring novel therapies to the forefront of medical treatments.

Conclusion

In conclusion, Stephen Richard Baker's relentless pursuit of innovation and his unwavering dedication to improving healthcare make him a standout figure in the field of inventions. With a keen focus on developing novel pharmaceutical solutions, Baker continues to shape the landscape of neurological and psychiatric treatments, leaving a lasting impact on the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…